Combining the results of identification of drugs targeting common pathways/genes and analysis of target genes of approved/investigational drugs, we suggested that JAK-STAT inhibitors may be potential common therapeutic drugs for MS and SS. Here, SOAT1 is linked to synovial sarcoma.